Inventiva (NASDAQ:IVA) Earns Neutral Rating from Analysts at UBS Group

UBS Group started coverage on shares of Inventiva (NASDAQ:IVA) in a research report released on Tuesday morning, MarketBeat.com reports. The firm issued a neutral rating and a $3.00 price target on the stock.

Other equities analysts have also issued research reports about the stock. Stifel Nicolaus reduced their price objective on shares of Inventiva from $25.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, September 26th. HC Wainwright reduced their price objective on shares of Inventiva from $14.00 to $13.00 and set a “buy” rating for the company in a research report on Tuesday, October 15th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $14.00.

Inventiva Stock Performance

Shares of NASDAQ:IVA traded up $0.03 during trading hours on Tuesday, hitting $2.69. 4,437 shares of the company’s stock traded hands, compared to its average volume of 77,337. Inventiva has a 52 week low of $1.53 and a 52 week high of $4.75. The company’s fifty day simple moving average is $2.32 and its two-hundred day simple moving average is $2.68.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Inventiva stock. Virtu Financial LLC bought a new position in Inventiva S.A. (NASDAQ:IVA) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 10,490 shares of the company’s stock, valued at approximately $38,000. Institutional investors and hedge funds own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.